Table 7.
Multivariable model assessing the effect on survival in patients with IPF.
| Total (n = 1,009) | Age group <75 years (n = 659) | Age group ≥75 years (n = 350) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| HR | 95%CI | p-value | HR | 95%CI | p-value | HR | 95%CI | p-value | ||
| Age group 75+ years | 1.49 | 1.20–1.85 | <0.001 | |||||||
| Female | 1.04 | 0.81–1.33 | 0.752 | 1.12 | 0.83–1.51 | 0.475 | 0.84 | 0.55–1.28 | 0.416 | |
| Duration since first IPF symptoms (years) | 0.98 | 0.95–1.00 | 0.088 | 0.99 | 0.96–1.02 | 0.623 | 0.92 | 0.86–0.98 | 0.009 | |
| BMI | 0.99 | 0.97–1.02 | 0.438 | 1.01 | 0.98–1.04 | 0.723 | 0.95 | 0.91–1.00 | 0.059 | |
| Number of comorbidities | 1.03 | 0.99–1.08 | 0.136 | 1.05 | 0.98–1.11 | 0.153 | 1.02 | 0.96–1.08 | 0.578 | |
| FVC | 0.98 | 0.98–0.99 | <0.001 | 0.99 | 0.98–0.99 | 0.002 | 0.98 | 0.97–0.99 | 0.004 | |
| GAP index | ||||||||||
| Stage I | 1.00 | 1.00 | 1.00 | |||||||
| Stage II | 1.91 | 1.34–2.74 | <0.001 | 2.11 | 1.40–3.18 | <0.001 | 1.83 | 0.81–4.15 | 0.149 | |
| Stage III | 3.51 | 2.35–5.23 | <0.001 | 4.13 | 2.60–6.57 | <0.001 | 1.28 | 0.45–3.62 | 0.644 | |
| Physician's global assessment of clinical course of IPF | ||||||||||
| Stable disease | 1.00 | 1.00 | 1.00 | |||||||
| Slow progression | 1.38 | 1.08–1.76 | 0.009 | 1.23 | 0.90–1.69 | 0.192 | 1.61 | 1.10–2.34 | 0.014 | |
| Rapid progression | 1.76 | 1.22–2.55 | 0.002 | 1.48 | 0.95–2.30 | 0.081 | 2.34 | 1.20–4.54 | 0.012 | |
| Antifibrotic therapy | 0.74 | 0.60–0.90 | 0.004 | 0.76 | 0.59–0.99 | 0.049 | 0.71 | 0.51–1.98 | 0.043 | |
IPF, idiopathic pulmonary fibrosis; BMI, body mass index; FVC, forced vital capacity; GAP, gender-age-physiology index; HRCT, high resolution computed tomography; NYHA, New York Heart Association.